Fundamental Analysis of BIOATLA INC(NASDAQ:BCAB) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BCAB. BCAB was compared to 564 industry peers in the Biotechnology industry. The financial health of BCAB is average, but there are quite some concerns on its profitability. BCAB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

BCAB had negative earnings in the past year.

In the past year BCAB has reported a negative cash flow from operations.

BCAB had negative earnings in each of the past 5 years.

BCAB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -131.46%, BCAB is not doing good in the industry: 83.12% of the companies in the same industry are doing better.

BCAB has a worse Return On Equity (-356.22%) than 76.84% of its industry peers.

		Industry Rank	Sector Rank
ROA	-131.46%
ROE	-356.22%
ROIC	N/A

ROA(3y)-62.62%

ROA(5y)-102.28%

ROE(3y)-93%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCAB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for BCAB has been increased compared to 1 year ago.

The number of shares outstanding for BCAB has been increased compared to 5 years ago.

BCAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

BCAB has an Altman-Z score of -13.60. This is a bad value and indicates that BCAB is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of BCAB (-13.60) is worse than 80.97% of its industry peers.

BCAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-13.6

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.11 indicates that BCAB has no problem at all paying its short term obligations.

The Current ratio of BCAB (3.11) is worse than 63.20% of its industry peers.

A Quick Ratio of 3.11 indicates that BCAB has no problem at all paying its short term obligations.

With a Quick ratio value of 3.11, BCAB is not doing good in the industry: 61.40% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	3.11
Quick Ratio	3.11

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.09% over the past year.

EPS 1Y (TTM)36.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%68.57%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BCAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.71% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y40.27%

EPS Next 2Y21.82%

EPS Next 3Y13.83%

EPS Next 5Y10.71%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BCAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BCAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BCAB's earnings are expected to grow with 13.83% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y21.82%

EPS Next 3Y13.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BCAB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOATLA INC

NASDAQ:BCAB (1/3/2025, 8:21:48 PM)

After market: 0.678 0 (0%)

0.678

+0.06 (+10.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-07 2024-11-07/amc

Earnings (Next)N/A N/A

Inst Owners50.54%

Inst Owner Change-18.87%

Ins Owners7.94%

Ins Owner Change-0.26%

Market Cap39.34M

Analysts84

Price Target10.88 (1504.72%)

Short Float %9.15%

Short Ratio3.76

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)20.8%

Min EPS beat(2)1.51%

Max EPS beat(2)40.09%

EPS beat(4)4

Avg EPS beat(4)21.37%

Min EPS beat(4)1.51%

Max EPS beat(4)40.09%

EPS beat(8)7

Avg EPS beat(8)13.21%

EPS beat(12)10

Avg EPS beat(12)9.93%

EPS beat(16)10

Avg EPS beat(16)-1.82%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)9.4%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-3.26%

EPS NY rev (1m)0%

EPS NY rev (3m)2.53%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.58
P/FCF	N/A
P/OCF	N/A
P/B	1.71
P/tB	1.71
EV/EBITDA	N/A

EPS(TTM)-1.7

EYN/A

EPS(NY)-1.34

Fwd EYN/A

FCF(TTM)-1.47

FCFYN/A

OCF(TTM)-1.47

OCFYN/A

SpS0.19

BVpS0.4

TBVpS0.4

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-131.46%
ROE	-356.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-62.62%

ROA(5y)-102.28%

ROE(3y)-93%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.18

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0.75%
Cap/Sales	0.07%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.11
Quick Ratio	3.11
Altman-Z	-13.6

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)33.23%

Cap/Depr(5y)66.74%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)36.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%68.57%

EPS Next Y40.27%

EPS Next 2Y21.82%

EPS Next 3Y13.83%

EPS Next 5Y10.71%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y33.52%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year29.03%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y2.57%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y2.22%

OCF growth 3YN/A

OCF growth 5YN/A

BIOATLA INC (BCAB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens